PEPTIDE BIOGRAPHIES

LYOPHILIZATION

The Science That Learned to Take Water Away Without Taking the Molecule With It

8-10 MIN READ

Introduction

Peptide lyophilization, commonly known as freeze-drying, transformed how fragile biological molecules could be preserved, stored and transported.

Long before peptides could be shipped across continents, stored for months, or kept as delicate powders inside sealed laboratory vials, researchers faced a deceptively simple problem.

Water keeps biology alive.

It can also help destroy it.

In solution, peptides and other biological molecules remain surrounded by the same medium in which many chemical reactions occur. Hydrolysis, oxidation, aggregation, deamidation and other degradation pathways can continue during storage. Raising the temperature to remove that water may accelerate degradation even further.

The solution that emerged was one of pharmaceutical science’s most elegant pieces of engineering: freeze the water first, then remove it without allowing it to become liquid again.

That process became known as lyophilization, or freeze-drying.

Today it is so familiar that the small white cake inside a pharmaceutical or research vial can appear almost unremarkable. Yet that powder represents more than a century of discoveries involving vacuum physics, ice formation, thermodynamics, protein chemistry, war medicine and pharmaceutical engineering.

For peptides in particular, lyophilization became one of the technologies that made long-term handling of fragile molecules practical.

Its story begins not with peptides, however, but with a much older challenge.

The Enemy Was Water

Biology depends on water.

Proteins fold in it. Peptides interact with receptors through environments shaped by it. Enzymes require it. Cells organize themselves around it.

But once a biological molecule has been isolated from the organism that produced it, water can become a liability.

Chemical reactions require molecular movement. In an aqueous solution, molecules are mobile. Reactive groups encounter one another. Oxygen can dissolve in the liquid. Peptide bonds and vulnerable amino-acid side chains may encounter chemical conditions that gradually alter the molecule.

For many proteins and peptides, keeping a compound in solution therefore creates a clock.

Cooling slows that clock.

Freezing slows it further.

But neither necessarily solves the problem completely.

Ordinary drying presents another problem. Removing water by heating a biological material can expose it to temperatures capable of altering its structure or accelerating chemical decomposition.

Scientists needed a way to remove water without cooking the molecule they were trying to preserve.

Freeze-drying provided an extraordinary workaround.

The principle relies on a physical phenomenon called sublimation.

Under appropriate temperature and pressure conditions, ice does not have to melt into liquid water before becoming vapor. It can move directly from the solid phase into the gas phase.

In modern pharmaceutical lyophilization, a solution is first frozen. The pressure surrounding it is then reduced. Carefully controlled heat supplies the energy needed for the ice to sublime while the product remains sufficiently cold to retain its structure.

After most of the ice has disappeared, more tightly associated water is removed during a secondary drying stage.

The U.S. Food and Drug Administration describes pharmaceutical lyophilization as three interdependent operations:

freezing, primary drying and secondary drying.

Simple in principle.

Remarkably difficult in practice.

The Problem

How Do You Preserve Something Too Fragile to Dry?

By the beginning of the twentieth century, scientists already understood a fundamental preservation problem.

Biological preparations deteriorated.

Serum, plasma, microorganisms, enzymes and other biological materials could lose their useful properties during storage. Refrigeration helped, but refrigeration itself was limited by the technology and infrastructure of the era.

Transportation made matters worse.

A biological preparation that behaved perfectly inside a laboratory refrigerator was not particularly useful if it could not survive a journey to another hospital, another city or eventually another continent.

Removing water offered an obvious solution.

Without sufficient water, many degradation processes become dramatically slower.

But biological materials were different from salt, minerals or many ordinary chemicals. They could not simply be heated until dry.

The structure of biological molecules could be altered in the process.

Researchers therefore began exploring an unusual idea:

What if the material were frozen first and dried while it remained frozen?

Experiments with drying biological materials under vacuum appeared in the early decades of the twentieth century. Jacques-Arsène d’Arsonval and others experimented with low-temperature vacuum drying, and in 1909 Leon Shackell described methods involving frozen biological materials and vacuum conditions. Historical accounts generally identify these experiments as important precursors to modern freeze-drying.

The fundamental insight was powerful.

Freezing could immobilize the material.

Vacuum could allow water to leave.

And low temperatures could reduce the destructive effects associated with conventional drying.

But an interesting physical principle is not yet a pharmaceutical manufacturing process.

That transformation would take another generation.

The Discovery

When Frozen Serum Learned to Survive

One of the pivotal chapters arrived in the 1930s.

At the University of Pennsylvania, Earl W. Flosdorf and Stuart Mudd worked on preservation methods for serum and other biological materials.

In 1935 they published an extensive paper describing a procedure and apparatus for preserving biological substances in what they called “lyophile” form.

The word was deliberate.

A lyophile was a dried material capable of readily taking up solvent again.

Their work helped move freeze-drying from an experimental curiosity toward a reproducible biological preservation technology.

This ability to remove water and later restore the material through reconstitution would become one of lyophilization’s defining advantages.

A biological preparation no longer had to remain permanently liquid.

It could exist in two states:

a dried storage state and a reconstituted working state.

That distinction would eventually become central to pharmaceutical manufacturing.

But history soon gave the technology an enormous and urgent test.

War.

During the Second World War, blood products were desperately needed far from the hospitals and laboratories where they were prepared.

Plasma offered important advantages for treating blood loss, but liquid biological materials were difficult to preserve and transport through wartime supply chains.

Freeze-dried plasma became one solution.

British, American and Canadian programs developed and deployed dried plasma and serum preparations during this period. Historical reviews describe wartime plasma preservation as one of the first major large-scale applications of freeze-drying technology.

Canada played a particularly interesting role.

Charles Best—already famous for his work with insulin—led Canada’s wartime blood-serum effort. Remarkably, researchers recently examined Canadian dried serum produced in the 1940s, demonstrating just how historically significant these preservation programs were.

Freeze-drying also became intertwined with another transformative medicine of the era: penicillin.

Early penicillin was extremely difficult to produce and purify, and the compound was vulnerable to conditions used in conventional processing. Low-temperature drying provided a way to obtain a dry preparation without subjecting it to destructive heat.

The lesson was becoming clear.

Freeze-drying was not simply a clever way to remove water.

It was a way to preserve molecules that conventional drying could not safely handle.

And that made it particularly attractive for the increasingly complex biological medicines that would arrive in the decades ahead.

The Journey

From Frozen Plasma to Peptide Vials

After the war, pharmaceutical science changed dramatically.

Antibiotics expanded.

Hormones became medicines.

Protein purification advanced.

Biotechnology eventually allowed researchers to manufacture recombinant proteins.

And peptide chemistry developed into its own major field.

Each advance increased the need to preserve molecules that could be chemically or physically unstable in solution.

Lyophilization increasingly became part of the pharmaceutical toolbox.

But researchers also discovered something important:

freeze-drying is not simply freezing followed by waiting for the water to disappear.

Every stage can affect the final product.

Freezing: The Step That Builds the Structure

The first stage determines much of what happens later.

As a formulation freezes, water begins forming ice crystals.

The peptide, salts, buffers and excipients generally do not enter those ice crystals in the same proportions. Instead, they become increasingly concentrated in the remaining unfrozen regions.

This phenomenon is known as freeze concentration.

A formulation that appeared chemically mild while liquid can therefore experience very different microscopic conditions while freezing.

Local concentrations can rise.

pH can shift.

Solutes can crystallize.

Interfaces form between ice and the concentrated solution.

Proteins and peptides can encounter stresses that did not exist before freezing began.

The size and distribution of ice crystals also matter because the spaces left behind by sublimated ice later become channels through which water vapor escapes.

A rapid freezing process tends to create different ice structures than a slower one.

For decades, much process development concentrated on the drying stages. Modern research has emphasized that this was incomplete. A major review of pharmaceutical lyophilization described freezing as one of the most complex and consequential parts of the entire process because it influences both product quality and drying performance.

The frozen structure effectively becomes the blueprint for the dried cake.

Primary Drying: Making Ice Disappear

Once frozen, chamber pressure is lowered.

Heat is carefully introduced.

This sounds contradictory.

Why add heat to something scientists are trying to keep frozen?

Because sublimation requires energy.

The challenge is supplying enough energy to move water vapor out efficiently without raising the product above a critical temperature at which its frozen structure may collapse or undergo undesirable change.

During primary drying, ice moves directly from solid to vapor.

A sublimation front gradually progresses through the frozen material.

Vapor travels through the porous dried layer and eventually reaches the freeze dryer’s condenser, where it is captured.

Primary drying is often the longest and most energy-intensive portion of the process.

Temperature and pressure must therefore be balanced carefully.

Higher shelf temperatures may accelerate sublimation.

Too much heat, however, can raise product temperature beyond its structural limits.

Modern lyophilization science treats this not as a fixed recipe but as an engineering design space involving product temperature, shelf temperature, chamber pressure, mass transfer and equipment capability.

Michael Pikal and colleagues were particularly influential in transforming pharmaceutical freeze-drying from empirical trial-and-error toward rational process engineering. Tang and Pikal’s widely cited 2004 review helped consolidate scientific principles for designing pharmaceutical freeze-drying cycles.

Secondary Drying: The Water That Ice Did Not Take

When the visible ice has sublimated, the product may look dry.

It is not necessarily finished.

Some water remains associated with the formulation even after the ice is gone.

During secondary drying, temperatures are generally increased under vacuum so that more of this bound or adsorbed water can leave the material through desorption.

The resulting amount of water remaining in the product is called residual moisture.

And here the story becomes more subtle.

It might seem logical that the driest peptide is automatically the most stable peptide.

That is not always true.

Too much residual moisture can increase molecular mobility and facilitate degradation.

Water can also act as a plasticizer, lowering the glass-transition temperature of an amorphous formulation and making molecular movement easier.

Yet excessive drying can also be undesirable for certain biological formulations.

Research therefore supports the idea of an optimal residual-moisture range rather than a universal rule that less water is always better.

That distinction is particularly important when discussing peptide stability.

The Legacy

The White Cake Is a Designed Material

One of the biggest misconceptions surrounding freeze-dried peptides is that lyophilization simply turns a liquid peptide into powder.

It does much more than that.

The final solid is a physical matrix whose properties depend on the peptide, solvent, buffer, excipients, freezing history, drying conditions and remaining moisture.

What appears inside the vial as a white cake is therefore not merely dried peptide.

It is the physical record of everything that happened during the lyophilization cycle.

Why Excipients Matter

Many lyophilized formulations contain ingredients specifically selected to protect the molecule or produce a suitable dried structure.

Sugars such as sucrose and trehalose are widely studied because they can help stabilize proteins and other biological molecules during freezing and drying.

Two major concepts have been proposed to explain this protection.

One is the water-replacement hypothesis.

Water normally participates in hydrogen-bonding interactions around biological molecules. When water disappears, certain sugars may form interactions that partly substitute for those normally supplied by hydration.

The second is vitrification.

During drying, sugars and other components may form an amorphous glass-like matrix with extremely low molecular mobility.

The molecule becomes, in a sense, trapped inside a molecularly quiet environment.

These mechanisms are not mutually exclusive, and modern stabilization science suggests that both molecular interactions and reduced mobility can contribute.

Other excipients may serve as buffers, bulking agents, surfactants or stabilizers.

Their selection matters.

A classic solid-state peptide study demonstrated that excipient type, residual moisture and temperature could significantly influence chemical reactivity in a lyophilized hexapeptide formulation.

In other words:

two vials containing the same peptide do not necessarily possess the same stability merely because both are lyophilized.

Their formulation and processing histories matter.

The Cake Can Tell a Story

A well-formed lyophilized cake is typically porous.

That porosity is useful.

When diluent is later added, liquid can move through those channels and dissolve the dried material relatively quickly.

But cake appearance can also reveal manufacturing problems.

Collapse, shrinkage or melt-back can indicate that the product experienced unsuitable thermal conditions.

Crystallization of certain components can alter both appearance and stability.

This is why pharmaceutical development evaluates characteristics such as:

cake appearance
residual moisture
reconstitution time
potency
degradation products
aggregation
particulate formation
sterility where required
container-closure integrity

A beautiful cake alone does not prove that the active molecule remains intact.

And an imperfect-looking cake does not automatically prove that the peptide has chemically failed.

Appearance is one quality attribute among many.

The Next Chapter

Freeze-Drying Becomes Precision Engineering

For much of its history, lyophilization was a batch process.

Thousands of filled vials could be loaded onto temperature-controlled shelves inside a large chamber, frozen together and subjected to the same pressure and shelf-temperature program.

That method works remarkably well.

It also contains inherent variability.

Vials near chamber walls may receive different amounts of radiant heat than vials in the centre.

Ice nucleation does not necessarily begin at the same temperature in every vial.

Different ice structures can therefore develop across the same batch.

Those differences can alter drying resistance and drying time.

Modern lyophilization research is increasingly attempting to control these variables rather than merely tolerate them.

Controlled Nucleation

One major area of development is controlled ice nucleation.

Instead of allowing individual vials to freeze spontaneously at random degrees of supercooling, engineers can encourage nucleation under more controlled conditions.

This can make ice-crystal structure and subsequent drying behavior more consistent.

Process Analytical Technology

Sensors and analytical tools increasingly allow manufacturers to understand what is occurring inside the chamber rather than relying entirely on preset time cycles.

Product temperature, chamber pressure, sublimation endpoints and other parameters can be monitored and modeled.

Mathematical Modeling

Modern process design increasingly uses first-principles heat- and mass-transfer models to predict primary drying rather than discovering suitable conditions only through repeated experimental batches.

Continuous Lyophilization

Researchers are also developing continuous freeze-drying systems, in which pharmaceutical units move through stages of the process instead of remaining in a single batch chamber.

Recent mechanistic research has modeled complete continuous lyophilization systems, reflecting the broader pharmaceutical movement toward continuous manufacturing.

Faster Energy Delivery

Microwave-assisted and hybrid lyophilization systems are also being investigated as potential ways to accelerate drying and improve energy transfer.

The goal is not to abandon the physics discovered a century ago.

It is to control that physics with far greater precision.

LYOPHILIZATION AND PEPTIDE STABILITY

Preservation Is Not Permanence

For peptide research, perhaps the most important lesson from the entire history of lyophilization is also the easiest to overlook.

Lyophilization slows degradation. It does not suspend chemistry forever.

Peptides can still undergo degradation in the solid state.

Potential pathways depend on sequence and formulation but may include:

oxidation
deamidation
isomerization
hydrolysis
aggregation
disulfide exchange
other sequence-specific reactions

Temperature still matters.

Moisture still matters.

Oxygen exposure can matter.

Light may matter for susceptible molecules.

The excipient system matters.

The physical state of the dried formulation matters.

And once the product is reconstituted, the stability environment changes dramatically because molecular mobility returns.

Reviews of peptide stability consistently identify conversion to a solid state as an important strategy for improving physical and chemical stability, while also emphasizing that formulation-specific degradation pathways remain possible.

This is why scientifically justified shelf life cannot be inferred from the word lyophilized alone.

Shelf-life claims require actual stability data generated under defined conditions.

Lyophilization is a preservation strategy.

It is not an expiration date.

Scientific Record

Foundational Discovery Papers

Flosdorf EW, Mudd S — 1935
Procedure and Apparatus for Preservation in “Lyophile” Form of Serum and Other Biological Substances
The Journal of Immunology, 29(5), 389–425
DOI: 10.4049/jimmunol.29.5.389. The Oxford Academic record includes the original paper/PDF.
Original paper — Oxford Academic

Greaves RIN — 1941
The Freezing of Human Serum and Plasma in Medical Research Council Transfusion Bottles, Before Drying by Sublimation from the Frozen State
Journal of Hygiene, 41(5–6), 489–495
DOI: 10.1017/S0022172400059775. This one is especially nice because the complete historic article is freely available through PubMed Central.
Free full text — PubMed Central

Franks F — 1998
Freeze-Drying of Bioproducts: Putting Principles into Practice
European Journal of Pharmaceutics and Biopharmaceutics, 45(3), 221–229
DOI: 10.1016/S0939-6411(98)00004-6.
PubMed record

Tang X, Pikal MJ — 2004
Design of Freeze-Drying Processes for Pharmaceuticals: Practical Advice
Pharmaceutical Research, 21(2), 191–200
DOI: 10.1023/B:PHAM.0000016234.73023.75. This is indeed the influential Tang/Pikal review we referenced.
PubMed record

Kasper JC, Friess W — 2011
The Freezing Step in Lyophilization: Physico-Chemical Fundamentals, Freezing Methods and Consequences on Process Performance and Quality Attributes of Biopharmaceuticals
European Journal of Pharmaceutics and Biopharmaceutics, 78(2), 248–263
DOI: 10.1016/j.ejpb.2011.03.010.
PubMed record

Major Research Milestones

Early 1900s — Drying Biology in the Frozen State

Experiments by scientists including d’Arsonval and Shackell demonstrate that biological material can be frozen and dehydrated under reduced pressure.

The fundamental preservation concept begins to emerge.

1935 — The “Lyophile”

Earl Flosdorf and Stuart Mudd publish their preservation system for serum and biological materials.

Freeze-drying moves toward a defined laboratory technology.

1940s — War Turns Preservation Into Necessity

Large-scale dried plasma and serum programs demonstrate the extraordinary logistical value of preserving biological material outside its normal liquid state.

Freeze-drying also becomes important in handling sensitive pharmaceutical substances during the antibiotic revolution.

Post-War Era — Pharmaceutical Expansion

Lyophilization spreads into antibiotics, vaccines, diagnostic materials, hormones and other heat-sensitive pharmaceutical products.

Biotechnology Era — Proteins Change the Challenge

Recombinant proteins and increasingly sophisticated biological medicines expose new problems involving aggregation, conformational stability, freezing stress and solid-state degradation.

Lyophilization science increasingly becomes formulation science.

1980s–1990s — The Glass State

Research into sugars, molecular mobility, glass transitions and water replacement provides a deeper molecular explanation for why certain excipients can protect dried biological molecules.

1990s–2000s — Freeze-Drying Becomes Engineering

Researchers including Michael Pikal develop increasingly quantitative approaches to heat transfer, mass transfer, product resistance and primary-drying optimization.

Trial-and-error begins giving way to rational cycle design.

2010s — Freezing Gets Its Due

Researchers increasingly recognize ice nucleation, freezing rate and frozen-state structure as critical process variables rather than simply preliminary steps.

2020s — Precision Lyophilization

Controlled nucleation, process analytical technology, mathematical modeling, continuous lyophilization and alternative energy-delivery systems push the field toward greater uniformity and efficiency.

A 2025 review of pharmaceutical freeze-drying described the technology as an important preservation platform for heat- and moisture-sensitive medicines including peptides, proteins and vaccines, while documenting the industry’s continuing movement toward better process understanding and control.

Reviews & Analysis

Modern lyophilization research is increasingly focused on precision, reproducibility, and peptide-specific stability rather than simply removing water. Current studies examine how freezing rate, ice nucleation, excipients, residual moisture, glass-transition behavior, and storage temperature influence the long-term integrity of sensitive biological compounds.

Recent reviews also emphasize the growing role of process analytical technology, mathematical modeling, controlled nucleation, and continuous freeze-drying. These tools are helping researchers better predict product temperature, drying endpoints, cake structure, and batch-to-batch variability.

For peptides, the central message remains consistent: lyophilization can greatly improve stability, but the final outcome depends on the entire formulation and process—not freeze-drying alone. Ongoing research continues to refine how peptides can be dried, stored, and later reconstituted while minimizing chemical and physical degradation.

Research Institutions

Lyophilization research spans pharmaceutical science, engineering, biotechnology, and formulation chemistry. Several institutions and research groups have played important roles in advancing the field:

University of Connecticut — associated with influential pharmaceutical freeze-drying research, including the work of Michael J. Pikal on cycle design, heat and mass transfer, and product stability.
University of Erlangen-Nürnberg — active in biopharmaceutical formulation and freeze-drying research, including work on freezing behavior, protein stability, and process development.
U.S. Food and Drug Administration (FDA) — provides regulatory guidance and scientific oversight related to lyophilized pharmaceutical products and manufacturing controls.
National Institute of Standards and Technology (NIST) and other process-science groups — contribute to measurement, modeling, and analytical approaches relevant to pharmaceutical manufacturing.
Pharmaceutical and biotechnology companies worldwide — continue to develop controlled nucleation, process analytical technologies, continuous lyophilization, and peptide- and protein-specific formulations.

Together, these groups have helped transform lyophilization from a preservation technique into a highly engineered pharmaceutical process.

Continue The Journey

Explore more peptide biographies and follow the stories behind the discoveries.